Atlas Venture
55 Grosvenor Street
London
England
W1K 3BW
United Kingdom
Tel: 44-0-20-7529-4444
Fax: 44-0-20-7529-4455
Website: http://www.atlasventure.com/
Email: london@atlasventure.com
32 articles with Atlas Venture
-
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
8/3/2022
AbCellera (Nasdaq: ABCL) and Atlas Venture announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company.
-
Venture partnerships won big this week, and genetic therapies-related startups raked in millions. Here’s where the money went.
-
Kurma Partners earned €160 million in the first closing of its Growth Opportunities fund, and Atlas Venture raked in its largest round of funding yet to invest in new biotech firms.
-
Atlas Venture raised $450 million at the close of its thirteenth fundraising activity to support efforts to create and invest in new biotech firms that address many unmet patient needs.
-
Rectify emerged with a goal to develop disease-modifying precision therapies that will restore ABC transporter function in order to address the underlying cause of serious genetic disease.
-
Atlas Venture Announces $300 Million Second Opportunity Fund
10/1/2021
Atlas Venture today announced the closing of its second Opportunity Fund, raising $300 million in an oversubscribed fundraise.
-
Atlas Venture Welcomes Samantha Truex as Venture Partner
5/10/2021
Atlas Venture, a leading early stage venture capital firm, announced that Samantha Truex is joining the firm as a venture partner.
-
Atlas Venture Welcomes Rajesh Devraj, PhD, as Venture Partner
11/16/2020
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced that Rajesh Devraj, PhD, is joining the firm as a venture partner.
-
Atlas Venture Announces $400 Million Fund XII and Expansion of Partnership
6/5/2020
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise.
-
With the close of the fund, Atlas Venture said it will continue to advance its mission of “doing well by doing good” and building biotech companies that will deliver high-impact therapies to patients.
-
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
1/27/2020
Quench Bio, a company leveraging new insights into gasdermin biology and innate immunology to develop medicines for severe inflammatory diseases, announced the completion of a $50 million Series A financing led by RA Capital Management, with participation from new Investor Abbvie Ventures.
-
Korro Bio Launched to Advance Groundbreaking New Approach to Nucleic Acid Editing
10/7/2019
Atlas Venture announced the launch of Korro Bio, Inc., a new company created to lead the rapidly advancing field of RNA editing.
-
In Wake of Terminations, Pharma Leaders Decry Actions That Will Limit Collaborations with Foreign...
8/23/2019
Leaders from across the pharmaceutical industry are decrying negative actions taken by government agencies and universities against Chinese researchers in the United States. -
Atlas Venture, F-Prime Capital, RA Capital Management, and Osage University Partners to Host Second Annual Science2Startup Symposium
4/12/2019
Science2Startup Symposium Will Take Place in Cambridge on April 23, 2019, at the Broad Institute of MIT and Harvard
-
In a reflection on the annual healthcare conference, VC Bruce Booth criticizes the high cost of attending JPM, as well as the focus on market share instead of patients.
-
Atlas Venture Announces $250 Million Opportunity Fund
1/2/2019
New fund will invest growth capital in Atlas-backed biotech companies
-
Generation Bio Appoints Jeff Jonas M.D. to its Board of Directors
6/7/2018
Generation Bio today announced the appointment of Jeff Jonas, M.D., chief executive officer of Sage Therapeutics, to its Board of Directors.
-
Atlas Venture Announces Andrea Armstrong Joins as Chief Talent Officer
6/5/2018
Andrea will lead the talent acquisition efforts for Atlas and work closely with companies incubating at Atlas and across the emerging portfolio on recruiting and organizational development.
-
Atlas Venture Announces That Nessan Bermingham Re-Joins as Venture Partner
2/6/2018
Nessan will be involved with the formation and leadership of groundbreaking new biotechnology companies as part of the Atlas platform.
-
Generation Bio is developing a breakthrough class of genetic medicines based on its proprietary GeneWave technology